ArticlePharmacogenomics2014
Genotype and risk of major bleeding during warfarin treatment.
Article in Pharmacogenomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01006733 (Genetics Informatics Trial), which is not on this map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetics Informatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis (DVT)
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.Clinical pharmacology and therapeutics · 2020Pooled it
- Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients.Saudi medical journal · 2016Pooled it
- Does One Size Fits All?Cardiovascular drugs and therapy · 2024Article
- Machine learning analysis of bleeding status in venous thromboembolism patients.Research and practice in thrombosis and haemostasis · 2024Article
- Real-world evidence that among atrial fibrillation patients warfarin is associated with reduced nonelective admissions compared with those on DOACs.Clinical cardiology · 2023Article
- A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with VariousDrug metabolism and disposition: the biological fate of chemicals · 2023Article
- Article
- The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.Clinical pharmacology and therapeutics · 2022Article
- Article
- Comparison of CYP2C9 Activity in Ethiopian and Non-Ethiopian Jews Using Phenytoin as a Probe.Frontiers in pharmacology · 2020Article
- Oral Anticoagulant Therapy-When Art Meets Science.Journal of clinical medicine · 2019Review
- Pharmacogenomics.Lancet (London, England) · 2019Review
- PGxO and PGxLOD: a reconciliation of pharmacogenomic knowledge of various provenances, enabling further comparison.BMC bioinformatics · 2019Article
- Association between four microRNA binding site-related polymorphisms and the risk of warfarin-induced bleeding complications.EXCLI journal · 2019Article
- Article
- Aspects of Modern Biobank Activity - Comprehensive Review.Pathology oncology research : POR · 2018Review
- Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.European journal of clinical pharmacology · 2018Article
- Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome.Clinical pharmacology and therapeutics · 2018Review
- Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.Circulation research · 2018Review
- The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development.Clinical pharmacology and therapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
aimTo determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy. MATERIALS &
methodsUsing Vanderbilt's DNA biobank we compared the prevalence of CYP2C9, VKORC1 and CYP4F2 variants in 250 cases with major bleeding and 259 controls during warfarin therapy.
resultsCYP2C9*3 was the only allele that differed significantly among cases (14.2%) and controls (7.8%; p = 0.022). In the 214 (85.6%) cases with a major bleed 30 or more days after warfarin initiation, CYP2C9*3 was the only variant associated with bleeding (adjusted odds ratio: 2.05; 95% CI: 1.04, 4.04).
conclusionThe CYP2C9*3 allele may double the risk of major bleeding among patients taking warfarin for 30 or more days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.